
|Articles|January 1, 2004
New Products & Services
Waltham, MA-Praecis Pharmaceuticals has received FDA approval to market abarelix (Plenaxis) for men with advanced prostate cancer.
Advertisement
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Theranostic therapies expand frontline use in prostate cancer
2
FDA removes warning labels on hormone replacement therapy
3
BioProtect Balloon Spacer shows sustained quality-of-life benefits in long-term study
4
Apalutamide vs Abiraterone Acetate RWE Outcomes in mCSPC
5




















